Proposed FDA Rule Could Bring Failure-To-Warn Liability

Law360, New York (January 23, 2014, 1:36 AM EST) -- A rule proposed by the U.S. Food and Drug Administration in early November could increase generic drug manufacturers' exposure to legal liability. Specifically, the FDA is proposing to amend 21 C.F.R. part 314 — Applications for FDA Approval to Market a New Drug, in order to allow generic drug manufacturers to update labels independently from brand-name manufacturers. According to the FDA, this rule would operate to permit generic drug manufacturers to update drug labels themselves when they acquire new information about a drug and submit a "changes being effected" ("CBE") supplement for the FDA's review. Under the current rule, only brand-name manufacturers can update labels and submit CBE supplements....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!